These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 3259038)
21. Do autochthonous tumors interfere with effector T cell responses? Blankenstein T Semin Cancer Biol; 2007 Aug; 17(4):267-74. PubMed ID: 17659881 [TBL] [Abstract][Full Text] [Related]
23. Adoptive cellular immunotherapy of cancer. Winter H; Fox BA Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690 [No Abstract] [Full Text] [Related]
24. T lymphocyte co-signaling pathways of the B7-CD28 family. Wang S; Chen L Cell Mol Immunol; 2004 Feb; 1(1):37-42. PubMed ID: 16212919 [TBL] [Abstract][Full Text] [Related]
25. [Effect of 3 different thymus extracts on T lymphocytes from patients with lymphoma and solid tumors in the advanced phase]. Ogier C; Moratelli S; Ballerini G Riv Emoter Immunoematol; 1983; 30(1):56-61. PubMed ID: 6605568 [No Abstract] [Full Text] [Related]
26. A novel T cell activation antigen identified by monoclonal IMN3.1 antibody and expressed preferentially on human T cells susceptible to apoptotic cell death. Uehara T; Miyawaki T; Natsuume-Sakai S; Nibu R; Hasui M; Yachie A; Shimizu S; Taniguchi N J Immunol; 1993 Apr; 150(8 Pt 1):3243-53. PubMed ID: 7682236 [TBL] [Abstract][Full Text] [Related]
27. Stimulation of human T lymphocytes via CD2 and CD3 molecules: establishment of the method and characterisation of proliferating cells. Bravo I; Carvalho GS Cytobios; 1993; 73(294-295):173-81. PubMed ID: 8099003 [TBL] [Abstract][Full Text] [Related]
28. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611 [TBL] [Abstract][Full Text] [Related]
29. CD4+CD57+ T cells derived from peripheral blood do not support immunoglobulin production by B cells. Andersson E; Ohlin M; Borrebaeck CA; Carlsson R Cell Immunol; 1995 Jul; 163(2):245-53. PubMed ID: 7541727 [TBL] [Abstract][Full Text] [Related]
33. Activation pathways for human T-lymphocytes defined by monoclonal antibodies against T-cell surface structures. Fleischer B Arzneimittelforschung; 1987 May; 37(5):585-6. PubMed ID: 3497639 [No Abstract] [Full Text] [Related]
34. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Li J; Hu P; Khawli LA; Epstein AL Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000 [TBL] [Abstract][Full Text] [Related]
35. Costimulation of memory T-cells by ICOS: a potential therapeutic target for autoimmunity? Sporici RA; Perrin PJ Clin Immunol; 2001 Sep; 100(3):263-9. PubMed ID: 11513539 [TBL] [Abstract][Full Text] [Related]
36. An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites. Kozarsky KF; Tsai C; Bott CM; Allada G; Li LL; Fox DA Cell Immunol; 1993 Sep; 150(2):235-46. PubMed ID: 8103706 [TBL] [Abstract][Full Text] [Related]
37. [Immunological status of patients with solid neoplasms]. Citterio F; Luciani G; Pozzetto U; Castagneto M Minerva Chir; 1980 May; 35(10):717-22. PubMed ID: 6969868 [No Abstract] [Full Text] [Related]
38. Cancer cells in effusions and increases in T-activated lymphocytes. Geuna M; Linari A; Bussolati G Eur J Cancer; 1990; 26(7):852-3. PubMed ID: 2145916 [No Abstract] [Full Text] [Related]
39. Activation of the immune system in cancer patients. Van Gool SW; Van Den Hove L; Ceuppens JL Med Pediatr Oncol; 2000 Jan; 34(1):1-9. PubMed ID: 10611577 [No Abstract] [Full Text] [Related]